CHARLOTTESVILLE, Va.--(BW HealthWire)--May 31, 2001--RHeoGene presented its most recent advances in protein receptor engineering today at the fourth annual meeting of the American Society for Gene Therapy (ASGT) in Seattle, Wash.
During the conference, Dr. Reddy Palli, group leader of receptor engineering at RHeoGene, presented new results from ongoing research that has created new forms of ligand-inducible, chimeric receptors. These receptor modifications will significantly improve the sensitivity, precision, and level of gene expression in mammalian cells -- three factors recognized as critical to the development of safe and effective new gene therapies. The new receptors will provide improved efficiency because they allow gene expression to be detected within three hours after ligand application.
``RHeoGene continues to improve inducible gene expression systems for application in the gene therapy market. New advancements in protein receptor engineering allow us to achieve one system that contains all the ideal attributes needed to enhance the use of regulated gene expression in a variety of research and commercial applications,'' said Palli. ``We foresee even greater improvements to the system increasing expression levels beyond the 20,000-fold enhancement already achieved in the work presented at ASGT.''
RHeoSwitch(TM) Technology for Human Therapeutics, Genomics, and Proteomics
RHeoGene's technology systems have important implications for advancements in gene therapy research. This technology has the ability to link the functions of genes, proteins, and complex cellular pathways for a multitude of applications, ranging from validating drug targets to discovery and development of new therapeutics for multiple diseases.
RHeoGene's RHeoSwitch(TM) inducible gene expression technology systems turn gene expression on and off, and allow it to be dialed up and down in a manner analogous to a rheostat control on a light switch. The system pairs the company's proprietary RHeoChem(TM) ligand inducers with proprietary RHeoCept(TM) receptor proteins to provide a powerful platform for regulating gene expression. According to Palli, RHeoGene's ongoing research program is designed to continue capturing the potential for this technology.
The company's RHeoPlex(TM) technology, a second-generation system, takes regulating gene expression to the next level by independently regulating expression levels of multiple genes inside the same cell.
RHeoGene
RHeoGene is the source for advanced applications, products, and technologies that manage gene expression. Seamlessly integrating biology and chemistry applications that deliver precise management of gene regulation, RHeoGene focuses on delivering customized inducible gene expression technology systems to advance drug discovery, functional genomics, proteomics, target validation, biotherapeutics production, and development of biosensors. RHeoGene's operations are located in Charlottesville, Va. and Spring House, Pa. For more information, visit www.rheogene.com. |
